Locally Advanced Pancreatic Cancer Clinical Trial
Official title:
Phase II Clinical Study of Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
This single-arm, Phase II clinical trial is to evaluate the efficacy and safety of nab-paclitaxel plus S-1 in locally advanced pancreatic cancer who were borderline resectable or unresectable .
This single-arm, Phase II clinical trial is to evaluate the efficacy and safety of
nab-paclitaxel plus S-1 in locally advanced pancreatic cancer who were borderline resectable
or unresectable . Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8,
S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day
cycle for 4-6 cycles.
During the study, if the subject's weight change was ≤10% from baseline, the dose was
calculated based on the measured value at baseline. If the change was >10%, the body surface
area of the subject should be recalculated and the dose administered should be adjusted. .
Study treatment period Borderline resectable: According to the results of imaging
examination, MDT discussed to determine the surgical resectability and timing of surgery. The
chemotherapy time was 4-6 cycles.
Unresectable: Chemotherapy for up to 6 cycles. According to the results of imaging
examination, MDT determined the resectability of the operation. It was decided by the
investigator and the patient to continue chemotherapy (S-1 maintenance), surgery or
radiotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Completed |
NCT01628458 -
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04276857 -
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT05988372 -
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
|
Phase 2 | |
| Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03126435 -
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
|
Phase 3 | |
| Completed |
NCT02035072 -
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
|
Phase 2 | |
| Enrolling by invitation |
NCT01063192 -
A Study of Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT06429904 -
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03885219 -
Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03468335 -
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
|
Phase 3 | |
| Not yet recruiting |
NCT03443921 -
Divestment for Artery-involved Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT03257033 -
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
|
Phase 3 | |
| Completed |
NCT02578732 -
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
|
Phase 2 | |
| Recruiting |
NCT04789980 -
Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
|
||
| Completed |
NCT00644618 -
Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy
|
Phase 3 | |
| Recruiting |
NCT03682289 -
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
|
Phase 2 | |
| Terminated |
NCT02404363 -
Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy
|
Phase 3 | |
| Active, not recruiting |
NCT06353581 -
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
|
Phase 2 | |
| Recruiting |
NCT02898649 -
Safety and Efficacy of Irreversible Electroporation for Locally Advanced Pancreatic Cancer
|
N/A |